Enzalutamide and lutetium-177–labeled prostate-specific membrane antigen-617 (LuPSMA) have both been proven to improve overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently. ...